Hanmi Pharm Signs $2.3 Billion Obesity Drug Deal with Genentech
Hanmi Pharm has signed a record-breaking $2.3 billion (3.2 trillion won) exclusive licensing deal with Roche's Genentech for its novel obesity drug candidate. Following the announcement, Hanmi Pharm's shares jumped by 30%.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (46/100)Sources
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy - Morningstar
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy Morningstar
Read full article →Hanmi signs record $2.3b obesity drug deal with Genentech
Hanmi Pharmaceutical said Monday it has inked an exclusive licensing agreement with Genentech for its obesity drug candidate HM17321 in a deal that could be worth up to $2.3 billion, setting new record for the firm for a licensing contract of a single drug candidate. Under the contract, Hanmi will receive an upfront payment of $190 million from Genentech, a US biotechnology subsidiary of Swiss multinational pharmaceutical giant Roche. The total value of the deal could reach as much as $2.3 billi
By The Korea Herald
Read full article →Hanmi Pharm signs 3.2 tln-won licensing deal with Roche's Genentech for obesity drug candidate
SEOUL, Aug. 24 (Yonhap) -- Hanmi Pharm. Co., a South Korean pharmaceutical compa...
By Choi Kyong-ae
Read full article →Hanmi Pharm shares jump 30% on Genentech obesity drug deal
By Investing.com
Read full article →Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy - Taiwan News
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy Taiwan News
Read full article →
